skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis

Journal Article · · Experimental Cell Research
; ; ; ;  [1];
  1. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603 (Japan)

Highlights: • Exosomal miR-16 increases in sera of experimental pulmonary fibrosis model mice. • miR-16 interferes with the mTORC2 component, Rictor. • miR-16 ameliorates pulmonary fibrosis by targeting the mTORC2-SPARC axis. Idiopathic pulmonary fibrosis (IPF), a progressive disorder of unknown etiology, is characterized by pathological lung fibroblast activation and proliferation resulting in abnormal deposition of extracellular matrix proteins within the lung parenchyma. The pathophysiological roles of exosomal microRNAs in pulmonary fibrosis remain unclear; therefore, we aimed to identify and characterize fibrosis-responsive exosomal microRNAs. We used microRNA array analysis and profiled the expression of exosome-derived miRNA in sera of C57BL/6 mice exhibiting bleomycin-induced pulmonary fibrosis. The effect of microRNAs potentially involved in fibrosis was then evaluated in vivo and in vitro. The expression of exosomal microRNA-16 was increased by up to 8.0-fold on day 14 in bleomycin-treated mice, compared to vehicle-treated mice. MicroRNA-16 mimic administration on day 14 after bleomycin challenge ameliorated pulmonary fibrosis and suppressed lung and serum expression of secreted protein acidic and rich in cysteine (SPARC). Pretreatment of human lung fibroblasts with the microRNA-16 mimic decreased the expression of rapamycin-insensitive companion of mTOR (Rictor) and TGF-β1–induced expression of SPARC. This is the first study reporting the anti-fibrotic properties of microRNA-16 and demonstrating that these effects occur via the mTORC2 pathway. These findings support that microRNA-16 may be a promising therapeutic target for IPF.

OSTI ID:
23195395
Journal Information:
Experimental Cell Research, Vol. 398, Issue 2; Other Information: Copyright (c) 2020 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0014-4827
Country of Publication:
United States
Language:
English

Similar Records

Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition
Journal Article · Fri Jun 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23195395

Obaculactone protects against bleomycin-induced pulmonary fibrosis in mice
Journal Article · Fri Jul 15 00:00:00 EDT 2016 · Toxicology and Applied Pharmacology · OSTI ID:23195395

Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2
Journal Article · Mon Jan 15 00:00:00 EST 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23195395